AnserBio Overview
AnserBio (previously ExoProTher Medical) is a biomedical start-up developing a novel approach to cancer treatment. The company targets the p53-based tumor suppression mechanism that is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. It uses proprietary cell derived nano-particles to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side effects. The company is in the preclinical stage.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Fighting cancer from within
ExoProTher Medical, a company developing a new approach to cancer treatment, is closing a seed funding round. The company utilizes the p53 protein, which is recognized as a genome protector, to treat brain cancer. The treatment involves injecting animal protein in the form of nanoparticles. The company has completed a $1 million seed private placement and has raised about $700,000 to date. They are also running a crowdfunding campaign to raise additional funds. ExoProTher Medical plans to begin human trials for their product within three years.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $6.45M |
| Last funding | $4M |
| Stage | Seed |
| Rounds | 6 |
| Investors | 3 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.anser-bio.com |
Locations
HaTa'asiya St, Nesher, Israel
Photos & Videos
3 item(s)
